SCHEMBL27136757

SCHEMBL27136757

Cc1cnn(-c2ccnc(C(F)(F)F)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.53
GRIN1 Q05586 2/20 0.53
GRIN2B Q13224 2/20 0.53
AR P10275 1/20 0.45
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
CYP17A1 P05093 3/20 0.39
EPHX2 P34913 1/20 0.38
LOXL2 Q9Y4K0 2/20 0.38
LOX P28300 1/20 0.37
KAT6A Q92794 1/20 0.37
PTGS2 P35354 2/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
IDO1 P14902 1/20 0.36
KCNT1 Q5JUK3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22725120 0.79 RXRA (0.48) RXRAGRIN1GRIN2BKDM4EALDH1A1
SCHEMBL27147409 0.78 RXRA (0.42) RXRAGRIN1GRIN2BARCYP17A1
SCHEMBL18086468 0.78 KDM4E (0.42) KDM4EALDH1A1HSD17B10SMN1; SMN2KAT6A
SCHEMBL27137469 0.77 RXRA (0.41) RXRAGRIN1GRIN2BARCYP17A1
SCHEMBL27142132 0.77 PTGS2 (0.43) RXRAGRIN1GRIN2BARLOXL2
SCHEMBL28876225 0.76 BTK (0.41) RXRAGRIN1GRIN2BAREPHX2
SCHEMBL15935175 0.75 RXRA (0.46) RXRAGRIN1GRIN2BARCYP17A1
SCHEMBL15832232 0.74 AR (0.46) RXRAGRIN1GRIN2BARKDM4E
SCHEMBL18529036 0.73 PDK2 (0.45) RXRAGRIN1GRIN2BARKDM4E
SCHEMBL27133083 0.73 ADRB1 (0.46) KDM4EALDH1A1HSD17B10CYP17A1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 WO disclosed